Beta-lactamase-producing nontypeable Haemophilus influenzae fails to protect Streptococcus pneumoniae from amoxicillin during experimental acute otitis media.
Acute otitis media (AOM) is the most common reason for outpatient antimicrobial therapy. Mixed infections pose a potential problem, since the first-line drug used for the treatment of AOM, amoxicillin, can be neutralized by beta-lactamase-producing pathogens of the upper respiratory tract. To study the effects of a 5-day course of amoxicillin on a mixed middle ear infection, rats were challenged with Streptococcus pneumoniae alone or in combination with beta-lactamase-producing nontypeable Haemophilus influenzae. Amoxicillin was introduced at the clinical peak of the infection. Local and systemic changes were monitored by otomicroscopy, bacterial culture, and analysis of histological changes and the expression of the transforming growth factor beta (TGF-beta) gene. beta-Lactamase-producing H. influenzae did not demonstrate an ability to protect S. pneumoniae. Amoxicillin eradicated the pneumococci in all treated animals but increased to some degree the ability of H. influenzae to persist at the site of infection. Thus, only an insignificant acceleration of the resolution of the AOM caused by a mixture of pathogens was observed during treatment. Moderate to major morphological changes could not be avoided by treatment of the mixed infections, but a slight downregulation of TGF-beta expression was observed. In contrast to infections caused by a single pathogen, the mixed infections induced white plaques in the tympanic membrane at a remarkably high frequency independent of treatment. These experimental findings constitute support for further studies of antimicrobial drugs and AOM caused by bacteria with and without mechanisms of antibiotic resistance.
Westman
Eva
E
Department of Oto-Rhino-Laryngology, Umeå University Hospital, Umeå, Sweden. va.borjesdotter.westman@lvn.se
Lundin
Susanne
S
Hermansson
Ann
A
Melhus
Asa
A
D000658:Amoxicillin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D003470:Culture Media; D004432:Ear, Middle / Q000382:microbiology; D006192:Haemophilus Infections / Q000382:microbiology; D006193:Haemophilus influenzae / Q000201:enzymology* / Q000502:physiology*; D008297:Male; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D010406:Penicillins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D011008:Pneumococcal Infections / Q000382:microbiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000378:metabolism*
D003470:Culture Media; D010406:Penicillins; D016212:Transforming Growth Factor beta; D000658:Amoxicillin; D001618:beta-Lactamases